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Low high-density lipoprotein predicts death in patients with
mild left ventricular dysfunction regardless of
coronary atherosclerosis
Tiziana Sampietroa, Federico Bigazzia, Mariarita Puntonic, Fabrizio Minichillia,
Patrizia Landia, Beatrice Dal Pinoa, Clara Carpeggiania and Antonio L’Abbatea,c
Objective Low plasma high-density lipoprotein (HDLAQ3 )-
cholesterol is a major risk factor for cardiovascular
diseases. We investigated whether HDL-cholesterol levels
had a prognostic value in patients with mild left ventricular
dysfunction, irrespective of the presence of coronary
disease.
Methods The study included 686 consecutive patients
hospitalized between January 2002 and December 2006
because of left ventricular dysfunction. All patients
completed lipid profile and underwent coronary
angiography. Patients were followed for a mean period of
23 months, during which major events were recorded.
Results Seventy-three percent patients were New York
Heart Association (NYHA) class I-II, with the mean values of
left ventricular ejection fraction and left ventricular end-
diastolic diameter being respectively 36.3W8.6% and
58.3W7.9mm. Half of the patients (52%) had HDL values
less than 40mg/dl, 28% presented with HDL less than
35mg/dl. In multivariable analysis, patients with HDL-
cholesterol concentration less than 40mg/dl showed
higher risk for cumulative mortality (HR 1.77, P<0.05) and
for cardiac death (HR 2.06, P<0.05). This higher risk was
also observed in patients with low HDL-cholesterol levels
but without significant coronary stenosis. The inclusion of
the CRP inflammation marker into the model highly
improved the power of death prediction.
Conclusion In patients with left ventricular dysfunction,
regardless of the presence of coronary atherosclerosis,
lower HDL-cholesterol was a strong and independent
predictor of both cardiac and all cause death. J Cardiovasc
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Introduction
Already 40 years ago, the Framingham study indicated
low plasmaHDL-cholesterol (HDL) as amajor risk factor
for cardiovascular diseases [1]. Further studies showed
HDL ability to predict death among the general popu-
lation as well as in specific groups [2]. It has been
proposed that low HDL levels are unable to remove
and transport cholesterol efficiently from peripheral
tissues to the liver (reverse cholesterol transport), thus
favoring cholesterol accumulation in the vascular wall [3]
and therefore coronary artery disease (CAD).
On the contrary, the number of coronary arteries affected
by significant coronary stenosis at angiography is a well
known powerful predictor of cardiac death, this variable
being largely used for risk stratification of hard cardiac
events [4].
Several studies have highlighted the complex relation-
ships between plasma concentration of HDL lipoproteins
and arterial wall homeostasis. In addition to acting in the
reverse cholesterol transport, HDLs preserve endothelial
functions and inhibit the inflammatory processes associ-
ated with cholesterol accumulation inside the vascular
wall [5,6]. Moreover, they increase endothelial bioavail-
ability of nitric oxide by binding to scavenger receptor
class B type 1 thus activating endothelial nitric oxide
synthase [7,8], which altogether might explain the
improved endothelium-dependent vasodilatation after
infusion of reconstituted HDLs [9]. It has also been
demonstrated that HDLs modulate other key control
mechanisms of microcirculation such as prostacyclin
[10], endothelium depolarizing factor [11] and endothelin
secretion [12], platelet activation [13] and cell prolifer-
ation [14]. Low levels of HDL can adversely affect the
vascular wall by activation of proinflammatory mechan-
isms, either nonspecific, such as the increase of C reactive
protein (CRP) [15], or specific of endothelium activation
such as expression of adhesion molecules [16] and even
cardiac function, according to both the experimental
evidence of HDLs’ myocardial protection from ischemia
reperfusion injury [17]. More recent research focuses on
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the potential direct HDLs role on idiopathic dilated
cardiomyopathy [18].
Considering the putative direct protective effect of
HDLs on coronary macro and micro-vessels, even
beyond the cholesterol pathway regulation, the aim of
the study was to investigate in a large cohort of patients
with left ventricular dysfunction, and with and without
coronary obstructive disease, the predictive value of
plasma HDLs concentration. In the same cohort, we also
investigated the potential additional role of inflammatory
markers, such as CRP, in risk stratification.
Methods
Study design and objective
This was a prospective cohort study aimed at evaluating
the prognostic value of low HDL lipoprotein in patients
with LVDys and angiographically documented coronary
anatomy. Study participants gave their written informed
consent and the study protocol gained ethical approval.
Patients and follow-up
From a total population of 1169 individuals with LVDys,
NYHA (New York Heart Association Classification) class
I-IV admitted to our cardiology department from January
2002 to December 2006, 686 consecutive patients
(546 males), were considered.
Diagnostic criterion for LVDys was left ventricular ejec-
tion fraction (LVEF) less than 45% at 2D-echocardio-
graphy. Exclusion criteria were: myocardial infarction
within the previous 6 months, congenital heart disease,
myocarditis, pericarditis, use of cardiac implantable
devices, severe renal insufficiency (<35ml/min according
to Cockroft–Gault formula [19]), cancer or other organ or
systemic diseases able to affect prognosis, coronary angio-
graphy not available. No exclusion criteria were applied
to traditional cardiovascular risk factors including age. All
patients underwent a lipid profile and the HDL cut-off
was set at 40 mg/dl in accordance with NCEP (ATP III)
guidelines [20] irrespective of sex.
Patients were followed up for amean period of 23months.
Follow-up data were obtained from review of the patient’s
record, personal communication from the patient’s
physician, telephone interview conducted by trained
personnel, or medical examination at the outpatient
clinic.
The documented outcome events were death for all
causes, cardiac death, nonfatal myocardial infarction
(MI) and revascularization procedure, as coronary artery
bypass grafting (CABG) or percutaneous coronary inter-
ventions (PCI). The cause of death was obtained from
medical records or death certificates. The classification of
cardiac death required the documentation of life-threa-
tening arrhythmias, or cardiac arrest, or acuteMI, or acute
left ventricular insufficiency or progressive congestive
heart failure. During the follow up, a total of 85 deaths
were recorded, 52 were classified as cardiovascular death,
eight patients died for sudden death and in eight cases
the cause of death was unknown.
With the exception of the high prevalence of males in our
population (80%), biases related to patient’s recruitment
and care can be assumed to be negligible; they were
admitted in the same period of time, in the same hospital
department and underwent the same diagnostic and
therapeutic procedures by the same medical staff.
Laboratory analyses and medical examinations
Information about anthropometric measures, arterial
pressure, glycemic state, lipid profile and smoke habit
was obtained. Hypertension was defined as sampling
systolic blood pressure at least 140mmHg or a diastolic
at least 90mmHg, or with patients on antihypertensive
drugs. Diabetes was diagnosed in presence of fasting
glucose levels higher than 126mg/dl in at least two
determinations or with patients on insulin/hypoglycemic
drugs. Patients were classified as affected by mild to
moderate renal failure when the estimated glomerular
filtration rate (eGFR), calculated according to Cockroft–
Gault formula [19], was at least 35 or at least 89ml/min
[21].
Total cholesterol, HDL and triglycerides were measured
in duplicate by standard enzymatic techniques (Synchron
CX9 Pro, Beckman Coulter, Inc., Fullerton USA). Low-
density lipoprotein (LDL) cholesterol was calculated
according to Friedewald formula. High-sensitivity CRP
was assayed by rate nephelometry (Behring BN 100,
DADE Behring, Italy).
Coronary angiography was performed in all patients;
coronary stenosis was defined as at least 50% lumen
diameter reduction of large epicardial vessels (corre-
sponding to 75% reduction in cross-section area). Diag-
nosis of coronary artery disease (CAD) was based on
the presence of at least one-vessel disease or previous
coronary revascularization procedures.
Statistical analysis
Data were expressed as meanSD, percentage or
logarithmic transformation was used when appropriate.
We performed Zeta test to evaluate the prevalence
differences of variables categorized according to HDL
quartiles or HDL NCEP-ATPIII cut-off (40mg/dl).
We used ANOVA test for comparison of means,
Mann–Whitney test for comparison between nonnormal
distributed variables, whereas, for categorical variables
we employed the Chi-square or Fischer’s exact test. The
relationship between HDL and coronary atherosclerosis
was adjusted for covariates such as age, sex, BMI, smok-
ing, diabetes, hypertension, renal failure, NYHA class,
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LVEF and medications (statins, b-blockers, ACE-
inhibitor); the relationship was evaluated by Poisson
regression models. Because of the high correlation
between HDL and triglycerides levels that can affect
the regression model by colinearity, triglycerides were
not included among confounding variables. Furthermore,
to evaluate the combined risk for cardiac or all cause
deaths during the follow-up, we performed a multivariate
survival analysis with the Cox proportional hazard ratio
(HR) model adjusted for the following cardiovascular risk
factors: age, sex, BMI, smoking, hypertension, diabetes,
renal failure, NYHA class, LVEF, medications (statin,
b-blockers, ACE-inhibitor) and CAD. In a subgroup of
546 patients, the role of CRP in HDL mortality predic-
tion was also studied.
All confidence intervals were estimated at the 95% level,
a P-value less than 0.05 was considered statistically
significant. The power-analysis test, performed to evalu-
ate the reliability of the findings, was 80%. STATA 8
analysis software (Stata Corp LP, College Station, Texas,
USA) was used.
Results
Descriptive analysis
Male individuals were 80% of the total population and
were significantly younger than females (66 11 vs.
70 9 years, P< 0.0001). Table 1 reports anthropometric
data, lipid profile, cardiac function parameters, CAD
prevalence, hypertension, diabetes, obesity, arrhythmias,
valvulopathies, mild or moderate renal failure, smoking
and pharmacological therapy in the whole population,
when patients were stratified by the HDLs cut-off and
when patients were grouped according to CAD diagnosis.
In 31% of patients we observed an average LDL con-
centration above the guideline cut-off (LDL<100mg/dl)
recommended for patients with CAD or coronary heart
disease risk equivalents. In more than half of our popu-
lation HDL levels were below 40 mg/dl; moreover, 28%
of patients (a prevalence nearly threefold the general
population) presented extremely reduced HDL concen-
trations (<35mg/dl).
As compared with patients with negative angiography (no
CAD), those with significant coronary stenosis (CAD) had
lower HDL levels (40.5 12.2 vs. 46.1 13.6mg/dl,
P< 0.0001), but lower prevalence of NYHA class III-
IV (23.4% vs. 40.8% P< 0.0001). In our population,
despite the high prevalence of CAD, less than half of
patients with documented atherosclerosis were on
statin treatment.
No significant correlation was found between HDL,
NYHA class, and LVEF in the whole population; never-
theless, in no CAD group, patients with HDL less than
40mg/dl showed a lower LVEF as compared with indi-
viduals with HDL at least 40mg/dl (31.4 7.1 vs.
35.5 8.2, adjusted P< 0.005) in accordance with the
higher prevalence of NYHA III-IV observed in those
with HDL less than 40mg/dl.
Results on inflammation status showed that CRP con-
centration were significantly higher in LVDys patients
with low HDL levels as compared with individuals
with HDL at least 40mg/dl (median 0.715, range
0.01–47.0 vs. 0.420, 0.02–16.5mg/dl, P< 0.0001) and
in LVDys patients with CAD as compared with individ-
uals without CAD (median 0.620, range 0.01–47.0 vs.
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Table 1 Baseline characteristics, lipid profiles, diseases and medications prevalence in the whole population and stratified according to the
high-density lipoproteins cut-off or coronary artery disease
Total (n 686) HDL <40 (n 354) HDL 40 (n 332) P CAD (n 534) No CAD (n 152) P
Age (range) 6610 (20–92) 6611 (34–90) 6710 (20–92) <0.05 6411 (34–90) 6710 (20–92) <0.005
Sex (male/female) 546/140 304/50 242/90 <0.0001 443/91 103/49 <0.0001
BMI (kg/m2) 26.94.1 27.44.1 26.44.0 <0.005 27.84.8 26.63.8 <0.005
Cholesterol (mg/dl) 183.543.1 168.235.8 199.544.3 <0.0001 180.841.5 192.747.0 <0.0001
Triglycerides (mg/dl) 122.689.3 131.1075.3 113.5101.4 <0.0001 122.171.6 124.1134.3 NS
HDL (mg/dl) 41.712.7 33.04.6 51.012.1 –AQ6 40.512.2 46.113.5 <0.0001
LDL (mg/dl) 117.435.4 108.830.1 126.438.2 <0.0001 116.334.4 122.238.1 NS
BMI>30 kg/m2 (%) 21 29 17 <0.01 17 25 <0.05
Smoking (%) 50 53 45.5 <0.05 53 37.5 <0.0005
NYHA class I-II (%) 73 74 71 NS 77 59 <0.0001
LVEF (%) 36.78.4 36.48.7 37.08.0 NS 37.58.3 34.08.0 <0.0001
LVEDD (mm) 57.97.6 57.77.6 59.87.7 NS 56.77.2 61.97.8 <0.0001
CAD (%) 78 84.7 70.5 <0.0001 – – –
Diabetes (%) 30 35.6 23.5 <0.0005 33 18.4 <0.0005
Hypertension (%) 43.1 42.7 43.7 NS 43.8 40.8 NS
Arrhythmias (%) 24.3 24 24.7 NS 19.7 40.8 <0.0001
Valvulopathies (%) 13.8 12.4 15.4 NS 11.4 22.4 <0.005
Renal failure (%) 7.6 7.3 7.8 NS 8.4 4.6 NS
Statins (%) 37.8 35.3 40.6 NS 42.9 20.3 <0.0001
b-blockers (%) 64.1 66.4 61.7 NS 65.2 60.5 NS
ACE-inhibitor (%) 53.1 53.4 52.7 NS 49.4 65.8 <0.0005
Reported P value is relative to (

) HDL <40 vs. HDL 40 or () CAD vs. no-CAD comparison. Values are MeanSD. Conversion Factor mg/dl to mmol/l: LDL, HDL,
CH¼0.02586; TG¼0.01129. BMI, body mass index; CAD, coronary artery disease; HDL, high density lipoprotein; LDL, low density lipoprotein; LVEDD, left ventricular
end diastolic dimension; LVEF, left ventricular ejection fraction; NS, not significant; NYHA, New York Heart Association.
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0.381, 0.01–11.2mg/dl, P< 0.0001). If we compare the
low-HDL/CAD group and the high-HDL/noCAD group,
the difference on CRP levels is maximized, median value
of the first group is more than double: 0.78 (0.01–4.70) vs.
0.35 (0.02–11.17) mg/dl P< 0.0001, suggesting that con-
dition characterized by atherosclerosis and reduced HDL
levels is associated with higher inflammatory response.
The Poisson regression analysis indicated that atheroscle-
rosis risk decreases by 1% (P< 0.01, after adjustment for
confounding variables) for each 1 mg/dl HDL increase.
Follow-up
During the follow-up, 32.4% of patients underwent cor-
onary revascularization (procedures performed at enrol-
ment -134 cases- were excluded). Results of coronary
angiography show: three or four partially occluded vessels
in 136 individuals, one or two stenotic vessels in 248
individuals, and a negative angiography in 168 individ-
uals. The mean time of revascularization after enrollment
is 12.3 months.
Table 2 shows distribution of events and statistical sig-
nificance according to HDL cut-off and to presence or
absence of significant CAD. Total revascularization pro-
cedures were more frequent in patients with HDL less
than 40mg/dl than in patients with HDL at least 40mg/dl
(38 vs. 27%, P< 0.005). Inferential analysis showed
a significant association between HDL levels and total
revascularization procedures: cumulative revasculari-
zation incidence rate increased by 62% in the subgroup
with HDL less than 40mg/dl as compared with the one
with HDL at least 40mg/dl (P< 0.005, after adjustment).
Five percentage of patients developed MI (n 34), with a
higher -but not significant- incidence in the subgroup
with low HDL (5.9 vs. 3.9%).
During follow up, a total of 85 deaths were recorded (the
15.2% in HDL<40 subgroup mg/dl and the 9.3% in HDL
40mg/dl subgroup, P< 0.05). The Cox analysis showed
an association betweenHDL levels and risk of cumulative
death: total mortality rate increase by 77% (P< 0.05, after
adjustment) in the group with HDL less than 40mg/dl as
comparedwith groupwithHDLat least 40mg/dl (Fig. 1a).
This result is well evident in Fig. 1b, where predicted
survival curves are stratified according to HDL quartiles:
moving from high to low HDL quartile the risk of total
mortality increases of 34% at each step (P< 0.01, after
correction). Also considering HDL as continuous variable,
the incidence rate decreases by 2.1% (P 0.08, after adjust-
ment) for each 1mg/dl increase in HDL.
Cardiac deaths were 61.2% of total deaths, this preva-
lence was more than double in HDL less than 40mg/dl
vs. HDL at least 40mg/dl group (10.5 vs. 4.5%,
P< 0.005); patients who died for cardiac causes had lower
HDL levels than those deceased for noncardiac causes
(36.0 8.9 vs. 43.5 17.9, P< 0.01 after correction). We
observe that patients with unclassified death (eight
patients died for sudden death and for eight patients
for unknown cause) show a prevalence of HDL less than
40mg/dl (69%) very similar to cardiac death group (71%).
Hence, supposing a casual distribution of these deaths,
the relationship between HDL and cardiac death should
not be influenced.
Inferential analysis indicated a very strong association
between low HDL levels and risk for cardiac deaths: we
postulated a risk reduction of 4.5% (P< 0.005, after
adjustment) for every HDL increase of 1 mg/dl; more-
over, individuals with HDL less than 40mg/dl showed a
106% death risk increase (HR 2.06 P< 0.05, after adjust-
ment, in the whole population Fig. 2a) as compared with
the HDL at least 40mg/dl group. In Fig. 2b the survival
curves have been compared for each HDL quartiles. Cox
analysis revealed that, moving from higher to lower HDL
quartile, the risk of cardiac death progressively increase
by 45% (HR 1.45 P< 0.01, in the whole population after
correction).
Patient population was further split into two subgroups
with or without CAD. In individuals with angiographi-
cally normal or near normal coronary arteries, HDL was
a good predictor of cardiac and cumulative mortality.
Accordingly, in the CAD negative group, patients with
HDL less than 40mg/dl had a 5.2-fold (P< 0.05,
adjusted) and 11-fold (P< 0.05, adjusted) higher prob-
ability of all causes death and cardiac mortality respect-
ively, as compared with those with high HDL (Fig. 3a
and b). In the CAD group, although in patients with
HDL less than 40mg/dl an increased death risk is evident
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Table 2 Prevalence distribution of recorded events according to 40 mg/dl HDL cut-off and according to CAD diagnosis
Total HDL<40 HDL 40 P# CAD no-CAD Py
PTCA

115 25.7% 16.0% P<0.005 29.5% 0% –
CABG

73 14.9% 11.6% NS 18.2% 0% –
Total coronary revasc

179 38.0% 26.9% P<0.005 45.5% 0% –
Cumulative death 85 15.2% 9.3% P<0.05 13.3% 9.2% NS
Cardiac death 52 10.5% 4.5% P<0.005 8.6% 3.9% P<0.05
Reported P value is relative to (#) HDL<40 vs. HDL 40 or (y) CAD vs. no-CAD comparison. () Intra-procedure mortality 0.4%; () intraprocedure mortality 1.3%; ()
patients (n 9) treated with both PTCA and CABG has been counted an only ones; procedures performed at enrolment 134 cases – were excluded. CABG, coronary
artery bypass graft; CAD, coronary artery disease; HDL, high density lipoprotein; NS, not significant; PTCA, percutaneous transluminal coronary angioplasty.
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(HR 1.44 to cumulative death, HR 1.75 to cardiac death)
the relationship did not have statistic relevance.
In a subgroup of 546 patients we tested also the pre-
dictive role of the CRP, a sensitive but relatively
nonspecific inflammatory marker for death prediction.
When we added CRP (categorized by 0.30mg/dl cut-
off) to the Cox model (Table 3), it significantly predicted
cumulative death (HR 2.45, P< 0.05 adjusted), whereas
it resulted only borderline in respect to cardiovascular
death (HR 2.39, P 0.08 adjusted).
Moreover, in order to evaluate the HDL and CRP prog-
nostic power as single or coupled variables, we imple-
mented an additional Cox model that included four
groups according to the generally accepted cut-off for
this variables (HDL <40mg/dl and CRP >0.30mg/dl):
low-HDL/low-CRP, low-HDL/high-CRP, high-HDL/
low-CRP, high-HDL/high-CRP.
As far as cumulativemortality is concerned, both groups –
high-HDL/high-CRP and low-HDL/low-CRP – had a
significantly higher risk than the reference ‘normal’ group
(high-HDL/low-CRP): the HR were respectively 5.0
(P< 0.05, adjusted) and 5.0 (P 0.05, adjusted), thus with
no significant difference between the two. However,
when the values of both risk factors were abnormal
(low-HDL/high-CRP), the predictive power of cumulat-
ive death in the whole population markedly increased to
HR 7.8 (P< 0.005, adjusted; Fig. 4).
The analysis of cardiac mortality showed that the
HDL and CRP predictive power barely reached a
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borderline significance as compared with the high-
HDL/low-CRP reference group: the HR was 5.5 for
low-HDL/low-CRP group (P 0.1, adjusted) and 6.7 for
high-HDL/high-CRP group (P 0.1, adjusted). Conver-
sely, when patients showed abnormal values of both
HDL and CRP, the predictive power for death widely
increased up to HR 10.8 (P< 0.05, adjusted).
Thus, in LVDys patients, lowHDL levels predicted both
cardiac and cumulative deaths, whereas the predictive
value of CRP was more striking for cumulative mortality.
Among the variables included in the Cox model, besides
HDL and CRP, advanced age (highest age quartile
included over 75 year patients), diabetes and renal
impairment significantly predicted cumulative mortality.
As far as cardiac death, the only additional significant
variable over advanced age was renal failure (Table 3).
In our population, the power-analysis showed a signifi-
cant relationship between HDL and each of the con-
sidered endpoints (revascularization 93%, cardiac death
82% and total death 78%), supporting the hypothesis of
predictive role of HDLs in LVDys mortality.
In spite of the fact that LDL was calculated indirectly,
based on HDL, TC and triglycerides levels, and being
aware that LDL is more sensitive than HDL to statin
therapy, we performed an additional multivariate
analysis replacing HDL with LDL in order to evaluate
the possible LDL contribution to outcome. LDL did not
show significant relationship with outcome, neither when
LDL was considered a continuous variable, nor when
patients were split into two subgroups, with LDL higher
or lower than 100mg/dl (data not shown).
Discussion
Previous studies have shown an inverse correlation
between plasma HDL and death rate in an apparently
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Table 3 Results of Cox’s multivariate survival analyses adjusted for
cardiovascular risk factors (age, sex, BMI, smoking, hypertension,
diabetes, renal disease, medications, LVEF and CAD)
Variables Hazard ratio 95% Confidence interval P
Cumulative death
HDL 1.85 1.00–3.40 <0.05
CRP 2.45 1.11–5.41 <0.05
Renal failure 3.64 1.86–7.14 <0.0001
Diabetes 1.83 1.02–3.28 <0.05
Advanced age

2.97 1.13–7.77 <0.05
Cardiac death
HDL 2.35 1.07–5.18 <0.05
CRP 2.39 0.89–6.41 0.08
Renal failure 3.31 1.41–7.94 <0.01
Only significant or borderline variables are reported in the table. Notes. (

) highest
age quartile: >75 years. CRP, C-reactive protein; HDL, high-density lipoprotein.
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healthy population [2]. More recently, other studies have
indicated a relationship between HDL levels and
mortality in LVDys condition at univariate analysis.
However, this association was not further confirmed after
adjustment of confounding factors [22–23].
In a population of relatively young patients mainly with
moderate LVDys (mean age 66 years, less than 9% of age
at least 80 years; 73% in NYHA class I-II), we have shown
that reduced HDL concentrations strongly predicted
short and medium-term mortality, the average follow-
up period being of approximately 2 years. HDLs resulted
able to predict both cumulative and cardiac mortality; this
was true irrespective of the presence of significant CAD.
LVDys patients without significant CAD but with HDL
less than 40mg/dl had a worse prognosis in respect to the
group with HDL at least 40mg/dl (Fig. 3).
The major limitation of our study stays, of course, in the
fact that it cannot establish a cause–effect relationship
between low HDLs and LVDys. Nevertheless, the
results of the present study solicit the hypothesis of a
pathogenetic role of HDLs in LVDys, beyond its con-
tribution to atherogenesis, which in turn prospects for
new therapeutic approaches. Endothelial dysfunction is
the common denominator of different vascular pathol-
ogies, in the \very early stages as well as in the stabilized
or complicated phases of the disease. It is well documen-
ted that the negative effects of low HDLs on endothelial
function are induced by numerous mechanisms – some
of which are still waiting delucidation – via vessel-wall
cholesterol-deposition, inflammation-antiinflammation
unbalance, increased LDL oxidation, reduced nitric
oxide bio-availability and impaired antithrombotic
effects. Indeed, endothelial dysfunction is a conditio sine
qua non for microvascular dysfunction, a disorder that
appears to be involved in the progression of LVDys
[24,25]. The recently reported direct effect of HDLs
on cardiac function further supports the possible role
of HDLs in the development of LVDys and its pro-
gression beyond the atherosclerotic burden [25,26].
Another limitation of this study is the lack of information
regarding exact indication for coronary revascularization
procedures and the incidence of hospitalization for
LVDys during follow up.
This is the first study to report the strong and indepen-
dent power of HDL in predicting cumulative/cardiac
death among patients with left ventricular dysfunction.
This data has its possible biologic basis on the recent
evidence of a myocardial protection against ischemia-
reperfusion injury [17] directly exerted by HDL, restor-
ation of vasomotor response to acetylcholine or sodium
nitroprusside [27], improved outcome following as much
as 10% increase in HDL concentration [28,29], and
reduction in the extension of atherosclerotic lesions
[30]. All together, this evidence evokes a therapeutic
potential for HDLs also in LVDys condition.
In LVDys prognostic assessment, a part from the other
variables considered such as advanced age, diabetes and
renal failure, CRP values less than 0.30mg/dl were
associated to a mortality risk five times higher as com-
pared with patients with low CRP. The combination of
HDL and CRP measurements improved death predic-
tion of cumulative and cardiac mortality: in LVDys
patients who had reduced levels of HDL and, at the
same time, high values of CRP concentration, the risk of
cumulative and cardiac deaths were 7.8 and 10.8 fold
respectively higher than in patient with HDL at least
40mg/dl and normal CRP levels. This finding could be
explained by the fact that lowHDL concentrations favors
inflammation, as revealed by higher CRP expression
levels observed both in idiopathic dilated cardiomyopa-
thy [15] and in hypoalphalipoproteinemia condition [18].
Our study identifies HDL-cholesterol plasma levels as
strong and independent predictor of mortality in patients’
whit left ventricular dysfunction being this or not of
postischemic nature. Considering the elevated preva-
lence of low HDL-C in LVDys patients (52% among
our study population), the HDLs rise as a novel potential
therapeutic target in the management of this pathological
condition.
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